Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: Implications for polypharmacy in schizophrenia

Behavioural Pharmacology

Volumn 23, Issue 7, 2012, Pages 658-668

  Sparkman, Nathan L ^a   Li, Ming ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

citalopram; depression; drug drug conditioning; haloperidol; olanzapine; Pavlovian conditioning; polypharmacy; rat; schizophrenia

Indexed keywords

CITALOPRAM; HALOPERIDOL; OLANZAPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; CONDITIONING; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; MALE; NONHUMAN; POLYPHARMACY; RAT; SCHIZOPHRENIA; STIMULUS RESPONSE; TREATMENT OUTCOME;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BENZODIAZEPINES; CITALOPRAM; CONDITIONING (PSYCHOLOGY); DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HALOPERIDOL; MALE; POLYPHARMACY; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA;

EID: 84866315910     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e328358590d     Document Type: Article

References (51)

1. Alfaro CL (2001). Emerging role of drug interaction studies in drug development: the good, the bad, and the unknown. Psychopharmacol Bull 35:80-93.
2. Aravagiri M, Teper Y, Marder SR (1999). Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20:369-377. (Pubitemid 30449775)
3. Arnt J (1982). Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol (Copenh) 51:321-329. (Pubitemid 12006638)
4. Biederman GB, Davey VA (1993). Antisickness conditioning using a nausea-producing nondrug cue. Behav Neurosci 107:215-217. (Pubitemid 23187272)
5. Botts S, Diaz FJ, Santoro V, Spina E, Muscatello MR, Cogollo M, et al. (2008). Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. Prog Neuropsychopharmacol Biol Psychiatry 32:1453-1458.
6. Buckley PF (2008). Factors that influence treatment success in schizophrenia. J Clin Psychiatry 69 (Suppl 3):4-10.
7. Cheng YF, Paalzow LK (1992). Linear pharmacokinetics of haloperidol in the rat. Biopharm Drug Dispos 13:69-76.
8. Conley RR, Kelly DL (2007). Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharmacol Bull 40:77-97.
9. Davey VA, Biederman GB (1991). Methodological issues in drug-drug conditioning in rats: nonassociative factors in heart rate and avfail. Behav Neurosci 105:850-859.
10. DeBattista C, DeBattista K (2010). Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyr-amidal and metabolic side effects. Curr Drug Saf 5:263-266.
11. DeBattista C, Hawkins J (2009). Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs 23:369-377.
12. Di Giovanni G, Di Matteo V, Di Mascio M, Esposito E (2000). Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse 35:53-61.
13. Di Matteo V, Cacchio M, Di Giulio C, Esposito E (2002). Role of serotonin(2C) receptors in the control of brain dopaminergic function. Pharmacol Biochem Behav 71:727-734. (Pubitemid 34219223)
14. Domjan M (2005). Pavlovian conditioning: a functional perspective. Annu Rev Psychol 56:179-206. (Pubitemid 40300783)
15. Englisch S, Knopf U, Scharnholz B, Kuwilsky A, Deuschle M, Zink M (2009). Duloxetine for major depressive episodes in the course of psychotic disorders: an observational clinical trial. J Psychopharmacol 23:875-882.
16. Franberg O, Wiker C, Marcus MM, Konradsson A, Jardemark K, Schilstrom B, et al. (2008). Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) 196:417-429. (Pubitemid 351200428)
17. Friedman JI, Ocampo R, Elbaz Z, Parrella M, White L, Bowler S, et al. (2005). The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia. J Clin Psychopharmacol 25:237-242. (Pubitemid 40685787)
18. Hashimoto S, Inoue T, Muraki I, Koyama T (2009). Effects of acute citalopram on the expression of conditioned freezing in naive versus chronic citalopram-treated rats. Prog Neuropsychopharmacol Biol Psychiatry 33:113-117.
19. Huang M, Ichiwaka J, Li Z, Dai J, Meltzer HY (2006). Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psycho-pharmacology (Berl) 185:274-281.
20. Hyttel J, Overo KF, Arnt J (1984). Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram. Psychopharmacology (Berl) 83:20-27. (Pubitemid 14141481)
21. Kapur S, Van der Spek SC, Brownlee BA, Nobrega JN (2003). Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625-631. (Pubitemid 36459179)
22. Koch S, Perry KW, Bymaster FP (2004). Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology 46:232-242. (Pubitemid 37532831)
23. Li M, Fletcher PJ, Kapur S (2007). Time course of the antipsychotic effect and the underlying behavioral mechanisms. Neuropsychopharmacology 32:263-272. (Pubitemid 46106933)
24. Li M, He W, Mead A (2009). An investigation of the behavioral mechanisms of antipsychotic action using a drug-drug conditioning paradigm. Behav Pharmacol 20:184-194.
25. Li M, Sun T, Zhang C, Hu G (2010). Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning. Psychopharmacology (Berl) 212:45-57.
26. Mead A, Li M (2009). Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: an interoceptive drug state mechanism. J Psychopharmacol 24 (7):1045-1053.
27. Mead A, Li M (2010). Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: an interoceptive drug state mechanism. J Psychopharmacol 24:1045-1053.
28. Porsolt RD, Moser PC, Castagne V (2010). Behavioral indices in antipsychotic drug discovery. J Pharmacol Exp Ther 333 (3):632-638.
29. Reilly S, Revusky S (1992). Drug-drug heart rate conditioning in rats: effective USs when pentobarbital is the CS. Pharmacol Biochem Behav 42:633-643.
30. Revusky S, Taukulis HK, Peddle C (1979). Learned associations between drug states: attempted analysis in Pavlovian terms. Physiol Psychol 7: 352-363. (Pubitemid 10127658)
31. Revusky S, Davey V, Zagorski M (1989). Heart rate conditioning with pentobarbital as a conditioned stimulus and amphetamine as an unconditioned stimulus. Behav Neurosci 103:296-307. (Pubitemid 19111647)
32. Rupnow MF, Greenspan A, Gharabawi GM, Kosik-Gonzalez C, Zhu Y, Stahl SM (2007). Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. Curr Med Res Opin 23 (11):2815-2822. (Pubitemid 350146419)
33. Salokangas RK, Saarijarvi S, Taiminen T, Kallioniemi H, Lehto H, Niemi H, et al. (1996). Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 94:175-180. (Pubitemid 26313289)
34. Sandson NB, Armstrong SC, Cozza KL (2005). An overview of psychotropic drug-drug interactions. Psychosomatics 46:464-494. (Pubitemid 46177967)
35. Sepehry AA, Potvin S, Elie R, Stip E (2007). Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry 68:604-610. (Pubitemid 46663044)
36. Spina E, Santoro V, D'Arrigo C (2008). Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 30:1206-1227.
37. Sun T, He W, Hu G, Li M (2010). Anxiolytic-like property of risperidone and olanzapine as examined in multiple measures of fear in rats. Pharmacol Biochem Behav 95:298-307.
38. Syvalahti EK, Taiminen T, Saarijarvi S, Lehto H, Niemi H, Ahola V, et al. (1997). Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res 25:24-32. (Pubitemid 27072952)
39. Taukulis HK (1996). Pavlovian conditioning to a diazepam cue with yohimbine as the unconditional stimulus. Neurobiol Learn Mem 65:223-232. (Pubitemid 26120434)
40. Taukulis HK, Brake LD (1989). Therapeutic and hypothermic properties of diazepam altered by a diazepam-chlorpromazine association. Pharmacol Biochem Behav 34:1-6. (Pubitemid 20008874)
41. Taukulis HK, Fillmore MT, Ruggles JL (1992). Neuroleptic-induced changes in the anxiolytic and myorelaxant properties of diazepam in the rat. Pharmacol Biochem Behav 41:13-21.
42. Wadenberg ML (2010). Conditioned avoidance response in the development of new antipsychotics. Curr Pharm Des 16:358-370.
43. Wadenberg ML, Hicks PB (1999). The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23:851-862. (Pubitemid 29458891)
44. Wadenberg ML, Soliman A, Van der Spek SC, Kapur S (2001). Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25:633-641. (Pubitemid 32995945)
45. Waldmeier PC, Delini-Stula AA (1979). Serotonin-dopamine interactions in the nigrostriatal system. Eur J Pharmacol 55:363-373. (Pubitemid 9195724)
46. Wilkin LD, Cunningham CL, Fitzgerald RD (1982). Pavlovian conditioning with ethanol and lithium: effects on heart rate and taste aversion in rats. J Comp Physiol Psychol 96:781-790.
47. Zhang C, Li M (2012). Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine. Behav Pharmacol 23:66-79.
48. Zhang C, Fang Y, Li M (2011). Olanzapine and risperidone disrupt conditioned avoidance responding by selectively weakening motivational salience of conditioned stimulus: further evidence. Pharmacol Biochem Behav 98:155-160.
49. Zink M, Englisch S, Meyer-Lindenberg A (2010). Polypharmacy in schizophrenia. Curr Opin Psychiatry 23:103-111.
50. Zisook S, Kasckow JW, Golshan S, Fellows I, Solorzano E, Lehman D, et al. (2009). Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. J Clin Psychiatry 70:562-571.
51. Zum Brunnen TL, Jann MW (1998). Drug interactions with antipsychotic agents: Incidence and therapeutic implications. CNS Drugs 9:381-401. (Pubitemid 28231415)